合作伙伴将对簿公堂！梅花生物遭味之素索赔

Core Viewpoint - Meihua Biological has been sued by Ajinomoto Co., Ltd. for allegedly infringing on two of its patents related to the production of L-glutamate and L-amino acids, with claims for significant financial damages totaling RMB 260 million [1][3]. Group 1: Legal Proceedings - Ajinomoto has filed a lawsuit in the Guangdong High Court, claiming that Meihua Biological and its subsidiaries have infringed on its patents during the production and sale of monosodium glutamate [1][3]. - The lawsuit requests an immediate cessation of the alleged infringing activities, destruction of equipment used for production, and compensation for economic losses amounting to RMB 130 million for each patent [3]. Group 2: Company Operations and Financial Performance - Meihua Biological maintains that its operations are normal and that it will actively respond to the lawsuit, emphasizing its commitment to protecting its and its shareholders' legal rights [4][7]. - The company has faced declining revenues and net profits in 2023 and 2024, with a reported net profit of RMB 3.025 billion in the first three quarters of 2025, reflecting a year-on-year increase of 51.61%, despite a revenue decline of 2.49% to RMB 18.215 billion [4][7]. Group 3: Corporate Governance and Market Impact - The company has stated that the legal issues involving its major shareholder, Meng Qingshan, who was sentenced for market manipulation, do not affect its operations or governance structure, as he has not held any position in the company since January 2017 [7]. - Following the announcement of the lawsuit and the shareholder's legal troubles, Meihua Biological's stock price fell by 2.35%, closing at RMB 10.37 per share, with a total market capitalization of RMB 29.08 billion [7].